论文部分内容阅读
目的对参麦注射液联合曲美他嗪治疗冠心病的临床疗效及安全性进行探讨。方法 60例冠心病患者,随机分为观察组和对照组,各30例,对照组应用曲美他嗪进行治疗;观察组在对照组的治疗基础上加用参麦注射液治疗。比较两组患者的疗效。结果观察组治疗总有效率90.00%显著高于对照组总有效率63.33%,差异有统计学意义(P<0.05)。结论参麦注射液联合曲美他嗪治疗冠心病临床疗效突出,具有良好的安全性。
Objective To investigate the clinical efficacy and safety of Shenmai injection combined with trimetazidine in the treatment of coronary heart disease. Methods Sixty patients with coronary heart disease were randomly divided into observation group and control group, 30 cases in each group. The control group was treated with trimetazidine. The observation group was treated with Shenmai injection on the basis of the control group. Compare the efficacy of two groups of patients. Results The total effective rate of observation group was 90.00%, significantly higher than that of control group (63.33%), the difference was statistically significant (P <0.05). Conclusion Shenmai injection combined with trimetazidine treatment of coronary heart disease clinical efficacy is outstanding, with good safety.